---
title: "Deutsche Bank: Raised the target price for POP MART from HKD 200.00 to HKD 303.00"
description: "Deutsche Bank: Raised the target price for POP MART from HKD 200.00 to HKD 303.00"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/243814052.md"
published_at: "2025-06-10T04:24:00.000Z"
---

# Deutsche Bank: Raised the target price for POP MART from HKD 200.00 to HKD 303.00

Deutsche Bank: Raised the target price for POP MART from HKD 200.00 to HKD 303.00

### Related Stocks

- [09992.HK - POP MART](https://longbridge.com/en/quote/09992.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Pop Mart meldet weltweiten Absatz von über 400 Millionen Einheiten im Jahr 2025 | Pop Mart International Group Ltd. announced that its total global sales in 2025 exceeded 400 million units across all IP | [Link](https://longbridge.com/en/news/275329932.md) |
| Pop Mart International Posts 2025 Group's Total Sales | Pop Mart International Group Ltd :IN 2025, GROUP'S TOTAL SALES ACROSS ALL IPS AND ALL PRODUCT CATEGORIES EXCEEDED 400 MI | [Link](https://longbridge.com/en/news/275334888.md) |
| Codeifai Enters AI-Backed Quantum Security Market | Codeifai Ltd :CODEIFAI ENTERS AI-BACKED QUANTUM SECURITY MARKETCOMPLETION OF ACQUISITION OF ANTENNATRANSFER.IOTOTAL CONS | [Link](https://longbridge.com/en/news/276015719.md) |
| Towa Pharmaceutical (TSE:4553) Margin Firmness Reinforces Defensive Earnings Narrative In Q3 2026 | Towa Pharmaceutical (TSE:4553) reported solid Q3 2026 results with revenue of ¥73.6b and net income of ¥8.9b, reflecting | [Link](https://longbridge.com/en/news/275991027.md) |
| Sino Biopharm Wins China Nod for New Lung Cancer Use of PD-L1 Drug | Sino Biopharmaceutical has received Chinese regulatory approval for its PD-L1 inhibitor, benmelstobart, for use as maint | [Link](https://longbridge.com/en/news/276016059.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
